Pharma BD Deal Intelligence

BioNTech SE / Scholar Rock Holding Corporation

2026 · Asset Purchase · $205M · Pending

BioNTech US Inc. agreed to purchase a U.S. FDA Rare Pediatric Disease Priority Review Voucher from Scholar Rock Holding Corporation for total cash consideration of $205 million. The voucher was awarded to Scholar Rock on September 11, 2026 upon FDA approval of ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy. A priority review voucher entitles the holder to a shortened FDA review clock for a single future marketing application. The purchase agreement was entered into on November 9, 2026 and disclosed on November 10, 2026. Consideration is payable in full at closing, which remains subject to customary conditions including expiration or termination of the Hart-Scott-Rodino waiting period. BioNTech has stated it intends to use the voucher for a late-stage oncology program but has not disclosed which candidate.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →